umeclidinium (Incruse Ellipta)

Introduction

FDA-approval recommended for combination with vilanterol

Indications

• COPD

Dosage

• 62 ug QD via inhalation (MDI)

Adverse effects

• nasopharyngitis
• upper respiratory tract infection
• cough
• arthralgia

• drug adverse effects of parasympatholytics

More general terms

• inhaled anticholinergic agent

Component of

• umeclidinium/vilanterol (Anoro Ellipta)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11519070
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11519069